What is the current Ivosidenib market size?

The Ivosidenib market size is approximately USD 1.2 billion as of 2023.

What is the growth forecast for the Ivosidenib market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driving future outlook.

What are the key drivers of the Ivosidenib market?

Increasing demand for targeted therapies and rising awareness of rare diseases are key drivers.

What are the challenges facing the Ivosidenib market?

High development costs and stringent regulatory requirements are major challenges.

Which regions are leading the Ivosidenib market?

North America and Europe are regional leaders, with significant market share.

Who are the top companies in the Ivosidenib market?

Agios Pharmaceuticals and other pharmaceutical giants are top companies, driving market growth.

What future opportunities exist in the Ivosidenib market?

Emerging markets and increasing use of combination therapies offer future opportunities.

How is technology impacting the Ivosidenib market?

Advances in precision medicine and digital health are transforming the market landscape.

What is the regulatory landscape for the Ivosidenib market?

Regulatory bodies are implementing policies to support innovation and patient access.

What is the expected impact of regulations on the Ivosidenib market size?

Regulations will influence the market size, with a focus on safety and efficacy.

Ivosidenib Growth Trends & Opportunity Analysis 2033

Ivosidenib by Application (Hospital, Pharmacy), by Types (60 Tablets, 30 Tablets), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 72

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.1%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 72

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.1%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Ivosidenib Market Size | CAGR 12.1 Forecast 2033

Ivosidenib Growth Trends & Opportunity Analysis 2033

Ivosidenib by Application (Hospital, Pharmacy), by Types (60 Tablets, 30 Tablets), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 72

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.1%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 72

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.1%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Ivosidenib Market Overview

The Ivosidenib market refers to the global industry focused on the development, manufacturing, and distribution of Ivosidenib, a medication used for the treatment of certain types of cancer. As a key player in the oncology pharmaceutical sector, the Ivosidenib market size is estimated to be around $183 million in 2025. The growth outlook for this market is promising, with a projected market forecast of $433 million by 2033, indicating a significant expansion of the industry. The Ivosidenib market is expected to experience a Compound Annual Growth Rate (CAGR) of 10.5% during the forecast period, driven by increasing demand for targeted cancer therapies and advancements in medical technology.

Loading chart…

Key forces shaping the Ivosidenib industry include technological advancements in cancer treatment, regulatory approvals, and competitive intensity among pharmaceutical companies. The largest region for the Ivosidenib market is currently North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing cancer prevalence and improving healthcare infrastructure. As the Ivosidenib market continues to evolve, it is essential for industry stakeholders to stay informed about the latest trends, challenges, and opportunities shaping the landscape of this critical sector.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.99 billion
Growth rate	CAGR of 12.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Servier Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Ivosidenib market is poised for significant growth, driven by increasing demand for targeted therapies in the treatment of acute myeloid leukemia (AML) and other cancers. As the Ivosidenib market size continues to expand, industry players are focusing on developing innovative treatments that cater to the evolving needs of patients and healthcare providers.

Growth Drivers2 items

The growing prevalence of AML and other cancers is driving the demand for Ivosidenib, resulting in a positive growth forecast for the market. Additionally, ongoing research and development activities are expected to lead to the discovery of new therapeutic applications for Ivosidenib, further fueling market growth.

The increasing adoption of precision medicine and targeted therapies is also contributing to the growth of the Ivosidenib market, as healthcare providers seek more effective and personalized treatment options for their patients. This trend is expected to continue, driven by advances in genetic testing and biomarker identification.

Restraints2 items

The high development costs and regulatory hurdles associated with bringing new cancer therapies to market are significant restraints on the Ivosidenib market. These challenges can limit the ability of smaller companies to enter the market and compete with established players.

The potential for Ivosidenib to be replaced by newer, more effective treatments is also a restraint on market growth, as the cancer treatment landscape is highly competitive and subject to rapid change. This risk can impact the long-term viability of investments in Ivosidenib research and development.

Opportunities2 items

The expanding Ivosidenib market presents opportunities for companies to develop combination therapies that leverage the benefits of Ivosidenib in conjunction with other treatments. This approach can help to improve patient outcomes and drive market growth.

The growing demand for Ivosidenib in emerging markets also represents a significant opportunity for industry players, as these regions often have limited access to advanced cancer treatments and are therefore more receptive to new therapies. Companies that can effectively navigate these markets and address local needs can gain a competitive advantage.

Challenges2 items

The Ivosidenib market faces challenges related to pricing and reimbursement, as the high cost of cancer therapies can be a barrier to access for many patients. Companies must balance their pricing strategies with the need to ensure that their treatments are accessible to those who need them.

The management of adverse events and side effects associated with Ivosidenib treatment is also a challenge, as these can have a significant impact on patient quality of life and treatment outcomes. Effective strategies for mitigating these risks are essential to the long-term success of Ivosidenib in the market.

Market Segmentation

Loading chart…

The Ivosidenib market can be segmented based on Application, which refers to the specific use cases of Ivosidenib in various industries. This segmentation category is crucial in understanding the Ivosidenib segmentation landscape, as it highlights the different areas where Ivosidenib is being utilized. The application segment includes subtypes such as [object Object] and [object Object], which are expected to contribute significantly to the overall Ivosidenib market size.

Another key segmentation category for the Ivosidenib market is Types, which encompasses the different forms or variations of Ivosidenib available in the market. This category is essential in market taxonomy, as it allows for a deeper understanding of the various Ivosidenib products and their respective market shares. The types segment includes subtypes such as [object Object] and [object Object], each with its unique characteristics and applications, ultimately influencing the overall Ivosidenib market size.

Ivosidenib Segmentation Breakdown6 items

Application

Hospital

Pharmacy

Types

60 Tablets

30 Tablets

Regional Insights

Loading chart…

The Ivosidenib market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of Ivosidenib and favorable policies supporting the development of targeted therapies.

Key drivers for North America include high infrastructure maturity, significant investments in research and development, and a well-established ecosystem. In Europe, factors such as rising demographics of targeted patient populations, increasing adoption of precision medicines, and supportive policies will contribute to the Ivosidenib market growth. Asia Pacific will be driven by growing demand for innovative therapies, expanding infrastructure, and rising investments in healthcare.

Latin America and Middle East & Africa will experience steady growth, driven by improving infrastructure, increasing adoption of Ivosidenib, and growing demand for targeted therapies. The regional forecast suggests that these regions will account for a smaller share of the global market, with Latin America holding around 10% and Middle East & Africa holding around 5%.

Competitive Landscape

The Ivosidenib market exhibits a moderately consolidated structure, driven by a mix of global players and local companies. The Ivosidenib competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals to maintain their market position, while local companies concentrate on pricing and distribution to gain market share.

Companies in the Ivosidenib market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. To overcome these challenges, companies must focus on competitive differentiation through technology, service model, channel strength, customization, and cost advantages. The following companies have adopted distinct strategic focuses:

Servier Pharmaceuticals regional expansion

Servier Pharmaceuticals innovation pipeline

Servier Pharmaceuticals premium pricing

Servier Pharmaceuticals local manufacturing

Servier Pharmaceuticals OEM tie-ups

Servier Pharmaceuticals vertical integration

Key Ivosidenib Companies1 items

Servier Pharmaceuticals

Market Ecosystem

The Ivosidenib ecosystem spans the upstream development of active pharmaceutical ingredients, the midstream manufacturing of the drug, and the downstream distribution and prescription of Ivosidenib to patients. It encompasses various stakeholders, including technology providers, suppliers, integrators, channels, and end users, who collectively create and capture value through the Ivosidenib value chain analysis.

Raw material/component suppliers — provide active pharmaceutical ingredients

OEMs / manufacturers — produce Ivosidenib

Technology providers — develop formulations and manufacturing processes

Distributors / channel partners — deliver Ivosidenib to healthcare providers

Service providers / after-sales — offer patient support and monitoring services

End users / buyers — prescribe and administer Ivosidenib to patients

Regulators/standards bodies — oversee approvals and compliance

In the Ivosidenib ecosystem, control points are primarily held by regulators and prescribers, who influence adoption through approvals and prescriptions. Dependency risks arise from input constraints, such as limited availability of active pharmaceutical ingredients, and standards and approvals that must be met. Switching costs are relatively high due to the complex nature of pharmaceutical manufacturing and the need for strict quality control. Partnerships between stakeholders are crucial to ensure interoperability and efficient distribution, and the ecosystem differs by region due to varying regulatory requirements and market conditions.

Recent Industry Insights

Recent developments in the Ivosidenib market have been driven by strategic partnerships and mergers & acquisitions. Over the last 12-18 months, key players have focused on expanding their product portfolios and enhancing their research capabilities. Notable product/technology launches have also been observed, with several companies introducing innovative solutions to cater to the evolving needs of the market. Moreover, regulatory changes have played a significant role in shaping the Ivosidenib industry trends, with authorities implementing new guidelines to ensure the safe and effective use of Ivosidenib.

The Ivosidenib industry trends are expected to be influenced by shifts in consumer or enterprise trends, with a growing demand for personalized medicine and targeted therapies. Additionally, funding rounds or expansions have been secured by several companies, enabling them to further invest in research and development. As the market continues to evolve, it is essential to stay informed about the latest developments and trends shaping the Ivosidenib industry.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Ivosidenib market outlook. The market attractiveness is moderate, driven by growing demand for targeted therapies in oncology. Competitive intensity is high, with multiple players vying for market share. The long-term outlook is promising, with potential for expansion into new indications. The innovation landscape is characterized by ongoing research into combination therapies and novel formulations. However, the demand–supply balance is a key risk factor, with potential disruptions to supply chains. Overall, the Ivosidenib market outlook is favorable, with opportunities for growth and innovation. Key risk factors include regulatory challenges and intense competition.

11 items

1. Executive Summary

2. Ivosidenib Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Ivosidenib Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Ivosidenib Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Pharmacy

6.2. Global Ivosidenib Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. 60 Tablets

6.2.2. 30 Tablets

6.3. Global Ivosidenib Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Ivosidenib Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Ivosidenib Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Ivosidenib Market Competition by Key Manufacturers

8.1. Global Ivosidenib Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Ivosidenib: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Servier Pharmaceuticals

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Ivosidenib Market

Figure 4: Global Ivosidenib Market: Drivers

Figure 5: Global Ivosidenib Market: Challenges

Figure 6: Global Ivosidenib Market: Trends

Figure 7: Global Ivosidenib Market: Opportunity

Figure 8: Global Ivosidenib Market: Restraint

Figure 9: Global Ivosidenib Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Ivosidenib Market Value (USD Million) By Region

Figure 15: Global Ivosidenib Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Ivosidenib Market Value (USD Million) By Region

Figure 23: Global Ivosidenib Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

55 items

Table 1: Market Segmentation Analysis

Table 2: Global Ivosidenib Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Ivosidenib Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Ivosidenib Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Ivosidenib Market Value (USD Million) By Region

Table 10: Global Ivosidenib Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Ivosidenib Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Ivosidenib Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Ivosidenib Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Servier Pharmaceuticals Basic Information And Sales Area

Table 31: Servier Pharmaceuticals. Products Portfolio

Table 32: Global Market Value (USD Million) (2025-2032) By Application

Table 33: Global Market Share (%) By Application (2032)

Table 34: Global Market Value (USD Million) (2025-2032) By Types

Table 35: Global Market Share (%) By Types (2032)

Table 36: Global Ivosidenib Market Value (USD Million) By Region

Table 37: Global Ivosidenib Market Share (%) By Region (2025-2032)

Table 38: North America Market Value (USD Million) (2025-2032) By Country

Table 39: North America Market Value (USD Million) (2025-2032) By Application

Table 40: North America Market Value (USD Million) (2025-2032) By Types

Table 41: Europe Market Value (USD Million) (2025-2032) By Country

Table 42: Europe Market Value (USD Million) (2025-2032) By Application

Table 43: Europe Market Value (USD Million) (2025-2032) By Types

Table 44: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 45: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 46: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 47: South America Market Value (USD Million) (2025-2032) By Country

Table 48: South America Market Value (USD Million) (2025-2032) By Application

Table 49: South America Market Value (USD Million) (2025-2032) By Types

Table 50: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 51: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 52: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 53: Research Programs/Design For This Report

Table 54: Key Data Information From Secondary Sources

Table 55: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Ivosidenib Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.99 billion
Growth rate	CAGR of 12.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Servier Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options